H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today and set a price target of $40.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mitchell Kapoor has given his Buy rating due to a combination of factors surrounding Cartesian Therapeutics’ promising developments. The initiation of the Phase 3 AURORA trial for Descartes-08, a CAR-T cell therapy targeting BCMA for myasthenia gravis, is a significant milestone. This trial is on schedule and aims to evaluate the therapy’s effectiveness in improving patients’ daily living activities without the need for preconditioning chemotherapy, which is a notable advantage.
Additionally, the positive results from the Phase 2b trial, where Descartes-08 demonstrated sustained efficacy and a favorable safety profile, bolster confidence in its potential. The anticipation of Phase 2 data for systemic lupus erythematosus in the latter half of 2025 further enhances the therapy’s prospects. A discounted cash flow analysis suggests a robust enterprise value, supporting a 12-month price target of $40, despite inherent risks such as trial delays and clinical data uncertainties.
In another report released on May 30, BTIG also reiterated a Buy rating on the stock with a $42.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue